Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

NCT ID: NCT03514069

Last Updated: 2025-01-08

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-05
• Study Completion Date: 2025-12-31

Brief Summary

The purpose of this study is to test how well the drug works, safety and tolerability of an investigational drug called Ruxolitinib in gliomas and glioblastomas, when combined with standard treatment for brain cancer, temozolomide and radiation.

Ruxolitinib is an experimental drug that works by targeting proteins in cells and stops them from growing. Ruxolitinib is experimental because it is not approved by the Food and Drug Administration (FDA) for the treatment of gliomas or glioblastomas

Temozolomide works by damaging the DNA of tumor cells so that they cannot divide properly. Some tumor cells can repair that damage and therefore be resistant to temozolomide.

Detailed Description

Primary Objective

Arm 1:

To determine Maximum tolerated dose (MTD) of ruxolitinib with radiation (2 Gy x 30) in patients with unmethylated MGMT high-grade glioma (HGG)

Arm 2:

To determine Maximum tolerated dose (MTD) of ruxolitinib with radiation (2 Gy x 30) and daily temozolomide at 75 mg/m2 in patients with methylated MGMT high-grade glioma (HGG)

Secondary Objective(s)

Arm 1:

• Safety of combination of ruxolitinib with radiation
• Progression free survival (PFS)
• Overall survival (OS)

Arm 2:

• Safety of combination of ruxolitinib with radiation and temozolomide
• Progression free survival (PFS)
• Overall survival (OS)

STUDY DESIGN

A phase 1 design will be used with cohorts of 3 patients treated at each dose level in both arms 1 and 2 and monitored for treatment-related toxicities. Escalation to the next dose will proceed in the absence of dose-limiting toxicities (DLTs).

Conditions

Glioma; Glioblastoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ruxolitinib + radiation x 60 Gy for 6 weeks

Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks

Group Type: EXPERIMENTAL

ruxolitinib

Intervention Type: DRUG

Starting dose ruxolitinib 10 mg twice daily

radiation

Intervention Type: RADIATION

60gy for 6 weeks

ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m

Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.

Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.

The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks

Group Type: EXPERIMENTAL

ruxolitinib

Intervention Type: DRUG

Starting dose ruxolitinib 10 mg twice daily

radiation

Intervention Type: RADIATION

60gy for 6 weeks

temozolomide

Intervention Type: DRUG

75mg/m2

Interventions

ruxolitinib

Starting dose ruxolitinib 10 mg twice daily

Intervention Type: DRUG

radiation

60gy for 6 weeks

Intervention Type: RADIATION

temozolomide

75mg/m2

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Arm 1:

• Patients must have unmethylated MGMT supratentorial high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).

Arm 2:

• Patients must have supratentorial methylated MGMT high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma).

Both:

• Patients must have MRI or CT with contrast within 28 days prior to starting treatment.
• Patients must have a Karnofsky performance status ≥ 70% (i.e. the patient must be able to care for himself/herself with occasional help from others).
• Patients must have adequate blood, kidney and liver function
• Patients must be able to provide written informed consent.
• Patients and their sexual partners must agree to avoid conception while on the study due to possible risks from experimental drugs. Women will need a negative pregnancy test to be on the study
• Patients may not have any other cancers except skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago

Exclusion Criteria

• Patients with other serious diseases
• Pregnant women
• Patients getting other cancer treatments
• Patients with other cancers except for localized skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago
• Patients who have had repeat craniotomy for tumor therapy after receiving radiation therapy and temozolomide treatment.
• Patients who have previously received other treatments for their cancers
• Patient has previously taken ruxolitinib or is allergic to components of the study drug
• Use of blood thinners
• Human immunodeficiency virus (HIV) infection
• Active hepatitis B or C infection
• Heart diseases including abnormal electrocardiogram (EKG)
• Patients unwilling or unable to follow this protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Case Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Peereboom, MD

Role: PRINCIPAL_INVESTIGATOR

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Locations

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland, Ohio, United States

Countries

United States

Other Identifiers

CASE3317

Identifier Type: -

Identifier Source: org_study_id